Molecular diagnostics and [18F]FDG-PET/CT in indeterminate thyroid nodules: complementing techniques or waste of valuable resources?

CONCLUSIONS: MD and [18F]FDG-PET/CT are both accurate rule-out tests when unresected nodules that remain unchanged on ultrasound follow-up are considered benign. It may vary worldwide which test is considered most suitable, depending on local availability of diagnostics, expertise, and cost-effectiveness considerations. Although complementary, the benefits of their combined use may be confined when therapeutic consequences are considered, and should therefore not routinely be recommended. In non-oncocytic ITN, sequential testing may be considered in case of a first-step MD negative test to confirm that withholding diagnostic surgery is oncologically safe. In oncocytic ITN, after further validation studies, MD might be considered.PMID:38009209 | DOI:10.1089/thy.2023.0337

Source: Thyroid : official journal of the American Thyroid Association - November 27, 2023 Category: Endocrinology Authors: Elizabeth J de Koster Hans Morreau Gysele S Bleumink Ilse van Engen-van Grunsven Lioe-Fee de Geus-Oei Thera P Links Iris M M J Wakelkamp Wim J G Oyen Dennis Vriens Source Type: research